| scholarly article | Q13442814 |
| P356 | DOI | 10.3727/096368911X600957 |
| P698 | PubMed publication ID | 21975034 |
| P50 | author | Martin H Bonamino | Q80405678 |
| Newton G Castro | Q39377669 | ||
| Helena Paula Brentani | Q43233374 | ||
| P2093 | author name string | Paulo Silva Belmonte-de-Abreu | |
| Pedro Setti-Perdigão | |||
| Hamilton Silva | |||
| Raffael Massuda | |||
| Antonio Galina | |||
| Bruna da Silveira Paulsen | |||
| Renata de Moraes Maciel | |||
| Stevens Kastrup Rehen | |||
| Leonardo Chicaybam | |||
| Cleide dos Santos Souza | |||
| Ernesto Nascimento Pozzatto | |||
| Hannah Drummond | |||
| Mariana Souza da Silveira | |||
| P2860 | cites work | Rethinking schizophrenia | Q22251086 |
| LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress | Q24294466 | ||
| Modelling schizophrenia using human induced pluripotent stem cells | Q24633007 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder | Q28251880 | ||
| Induced pluripotent stem cells from a spinal muscular atrophy patient | Q29614340 | ||
| Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons | Q29616199 | ||
| A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells | Q29619964 | ||
| Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative? | Q33342771 | ||
| Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. | Q33871319 | ||
| Low O2 tensions and the prevention of differentiation of hES cells | Q33932268 | ||
| Energy metabolism in human pluripotent stem cells and their differentiated counterparts | Q33940583 | ||
| Catching up on schizophrenia: natural history and neurobiology | Q34122141 | ||
| Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia | Q34137363 | ||
| Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. | Q34332628 | ||
| Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner | Q34477409 | ||
| Oxidative stress in schizophrenia: An integrated approach | Q34494844 | ||
| Generation of human induced pluripotent stem cells from dermal fibroblasts | Q34588555 | ||
| The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? | Q34630060 | ||
| The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases | Q34679230 | ||
| Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene | Q35015897 | ||
| Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine | Q35020740 | ||
| Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting | Q35030912 | ||
| Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence | Q36082300 | ||
| NADPH oxidase is required for the sensory plasticity of the carotid body by chronic intermittent hypoxia. | Q37217629 | ||
| Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage | Q37425341 | ||
| Redox dysregulation, neurodevelopment, and schizophrenia | Q37501168 | ||
| Upregulation of mitochondrial function and antioxidant defense in the differentiation of stem cells. | Q37595852 | ||
| Worldwide survey of published procedures to culture human embryonic stem cells | Q37669453 | ||
| Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation | Q37734466 | ||
| Feeder-free derivation of induced pluripotent stem cells from human immature dental pulp stem cells | Q39764925 | ||
| Cytoprotection by lithium and valproate varies between cell types and cellular stresses | Q40283107 | ||
| Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells. Novel evidence of the occurrence of NAD(P)H oxidase activity. | Q40424738 | ||
| Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts | Q40579019 | ||
| Reactive oxygen species and Alzheimer's disease. | Q41615924 | ||
| Nox4-dependent H2O2 production contributes to chronic glutamate toxicity in primary cortical neurons. | Q43110515 | ||
| Vitamin C enhances the generation of mouse and human induced pluripotent stem cells | Q43207059 | ||
| Determination of reactive oxygen species associated with the degeneration of dopaminergic neurons during dopamine metabolism. | Q43218756 | ||
| Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia | Q43801006 | ||
| The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide | Q44505340 | ||
| Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells | Q46792440 | ||
| Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. | Q48291254 | ||
| Mitochondrial creatine kinase activity prevents reactive oxygen species generation: antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity | Q48401459 | ||
| Agathisflavone enhances retinoic acid-induced neurogenesis and its receptors α and β in pluripotent stem cells. | Q53271220 | ||
| Induced Pluripotent Stem (iPS) Cell Research Overview | Q55053479 | ||
| P433 | issue | 7 | |
| P921 | main subject | schizophrenia | Q41112 |
| patient | Q181600 | ||
| neurogenesis | Q1456827 | ||
| P304 | page(s) | 1547-1559 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Cell Transplantation | Q15761863 |
| P1476 | title | Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient | |
| P478 | volume | 21 |
| Q26770097 | A Dishful of a Troubled Mind: Induced Pluripotent Stem Cells in Psychiatric Research |
| Q35162311 | A guide to generating and using hiPSC derived NPCs for the study of neurological diseases |
| Q38786732 | A new era of disease modeling and drug discovery using induced pluripotent stem cells |
| Q46970598 | Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. |
| Q34406924 | Accelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species |
| Q38654015 | Advances in Applications of Metabolomics in Pluripotent Stem Cell Research. |
| Q35904650 | Altered WNT Signaling in Human Induced Pluripotent Stem Cell Neural Progenitor Cells Derived from Four Schizophrenia Patients |
| Q39231042 | Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia |
| Q38809416 | Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence |
| Q45354529 | Aripiprazole, an atypical antipsychotic drug, improves maturation and complexity of neuroblast dendrites in the mouse dentate gyrus via increasing superoxide dismutases |
| Q47938598 | Changing the Diagnostic Concept of Schizophrenia: The NIMH Research Domain Criteria Initiative. |
| Q28353981 | Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models |
| Q35633578 | Co-expression network of neural-differentiation genes shows specific pattern in schizophrenia |
| Q39017298 | Common developmental genome deprogramming in schizophrenia - Role of Integrative Nuclear FGFR1 Signaling (INFS). |
| Q37217420 | Comparative neuronal differentiation of self-renewing neural progenitor cell lines obtained from human induced pluripotent stem cells |
| Q37433685 | Comprehensive characterization of genomic instability in pluripotent stem cells and their derived neuroprogenitor cell lines |
| Q37680999 | Concise review: drug discovery in the age of the induced pluripotent stem cell |
| Q42331751 | Dopaminergic differentiation of schizophrenia hiPSCs |
| Q52682637 | Dynamic Changes of the Mitochondria in Psychiatric Illnesses: New Mechanistic Insights From Human Neuronal Models. |
| Q36255210 | Evidence of Mitochondrial Dysfunction within the Complex Genetic Etiology of Schizophrenia. |
| Q34608239 | Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders |
| Q27692698 | From "directed differentiation" to "neuronal induction": modeling neuropsychiatric disease |
| Q58719784 | Generation of iPSC-Derived Human Peripheral Sensory Neurons Releasing Substance P Elicited by TRPV1 Agonists |
| Q33790547 | Genetically-Informed Patient Selection for iPSC Studies of Complex Diseases May Aid in Reducing Cellular Heterogeneity |
| Q42155770 | Harmine stimulates proliferation of human neural progenitors. |
| Q89633106 | Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises |
| Q38596601 | Human Inducible Pluripotent Stem Cells and Autism Spectrum Disorder: Emerging Technologies |
| Q34469459 | Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons |
| Q38211497 | Human-induced pluripotent stem cells: potential for neurodegenerative diseases |
| Q36208256 | Implications of aneuploidy for stem cell biology and brain therapeutics |
| Q37058606 | Increased abundance of translation machinery in stem cell-derived neural progenitor cells from four schizophrenia patients. |
| Q26772019 | Induced Pluripotent Stem Cells as a Novel Tool in Psychiatric Research |
| Q57176963 | Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism |
| Q37720208 | Induced pluripotent stem cells from patients with focal cortical dysplasia and refractory epilepsy. |
| Q34303709 | Induced pluripotent stem cells: the new patient? |
| Q52431644 | Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. |
| Q38170728 | Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells |
| Q35056065 | Modeling human neurological disorders with induced pluripotent stem cells |
| Q39130188 | Modeling neurodevelopmental and psychiatric diseases with human iPSCs |
| Q30446669 | Modeling psychiatric disorders at the cellular and network levels |
| Q37199033 | Modeling psychiatric disorders: from genomic findings to cellular phenotypes |
| Q42099548 | Modeling schizophrenia using induced pluripotent stem cell-derived and fibroblast-induced neurons |
| Q52372478 | New considerations for hiPSC-based models of neuropsychiatric disorders. |
| Q30774039 | Oxidative stress and schizophrenia: recent breakthroughs from an old story |
| Q34276729 | Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia |
| Q37121491 | Pluripotent stem cells as a model to study non-coding RNAs function in human neurogenesis |
| Q38714328 | Pluripotent stem cells in disease modelling and drug discovery |
| Q35761135 | Probing disorders of the nervous system using reprogramming approaches |
| Q38903697 | Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia |
| Q38739919 | Revisiting Mitochondrial Function and Metabolism in Pluripotent Stem Cells: Where Do We Stand in Neurological Diseases? |
| Q38766074 | SOD3 Ameliorates Aβ25-35-Induced Oxidative Damage in SH-SY5Y Cells by Inhibiting the Mitochondrial Pathway |
| Q38777693 | SOD3 Ameliorates H2O2-Induced Oxidative Damage in SH-SY5Y Cells by Inhibiting the Mitochondrial Pathway |
| Q89487559 | Stem Cells for Improving the Treatment of Neurodevelopmental Disorders |
| Q92394696 | Stem Cells in Psychiatry |
| Q39202144 | Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder |
| Q34845881 | Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells |
| Q92394719 | Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases |
| Q47875785 | The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening |
| Q89553658 | The evolution of stem cells, disease modeling, and drug discovery for neurological disorders |
| Q99631807 | The potential of induced pluripotent stem cells for discriminating neurodevelopmental disorders |
| Q36848272 | The proteome of schizophrenia |
| Q58730340 | Tracing Early Neurodevelopment in Schizophrenia with Induced Pluripotent Stem Cells |
| Q35231766 | Transcriptomics of maternal and fetal membranes can discriminate between gestational-age matched preterm neonates with and without cognitive impairment diagnosed at 18-24 months |
| Q38637625 | Using hiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms |
| Q42347521 | What if it was easier to prevent schizophrenia than to treat it? |
| Q37131089 | Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) be useful for schizophrenia research? |
| Q28582619 | Zika virus disrupts molecular fingerprinting of human neurospheres |
| Q50233440 | hiPSC-derived neural stem cells from patients with schizophrenia induce an impaired angiogenesis. |
| Q90284058 | iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function |
Search more.